Accreditation: 8.50 Nursing Contact Hours | 8.50 ABIM MOC II | 8.50 ACPE Pharmacy | 8.50 AMA PRA Category 1 Credit™
Venue: New York Marriott at the Brooklyn Bridge, 333 Adams Street, NY, United States
Official conference page for 2026 Brooklyn Lung Cancer Conference. https://binaytara.org/projects/conferences/2026-brooklyn-lung-cancer-conference
Day 1: Saturday, August 8th, 2026
All timings are in Eastern Time (EDT, GMT-04:00) time.
Session Chair: Joshua Sabari, MD
08:05 AM - 08:15 AM
EGFR-Mutant NSCLC: Sequencing Therapy After 1L Options – Julia Rotow, MD
08:15 AM - 08:25 AM
Mechanisms of Resistance in EGFR-Mutant Lung Cancer: What Matters Clinically?
08:25 AM - 08:35 AM
Local Therapy in EGFR-Mutant NSCLC: – Saumil Gandhi, MD, PhD
08:35 AM - 08:45 AM
Managing Toxicities of Modern Targeted Therapies: Practical Pearls – Isabel Preeshagul, DO
08:45 AM - 09:05 AM
Case-Based Discussion
Session Chair: Vamsi Velcheti, MD
09:05 AM - 09:15 AM
ALK-Positive NSCLC in 2026: Sequencing Beyond Lorlatinib – Sarah Waliany, MD
09:15 AM - 09:25 AM
ROS1-Positive NSCLC: Resistance and Emerging Therapies – Ashish Saxena, MD, PhD
09:25 AM - 09:35 AM
RET Fusion NSCLC: Current Standards and Future Directions – Rajwanth Veluswamy, MD
09:35 AM - 09:45 AM
HER2-Mutant NSCLC: Where do ADCs fit? – Balazs Halmos, MD
09:45 AM - 10:05 AM
Case-Based Discussion
Session Chair: Rajwanth Veluswamy, MD
10:30 AM - 10:40 AM
Current Standards for KRAS G12C NSCLC: Where Are We Today? – Grace Dy, MD
10:40 AM - 10:50 AM
The Path to Frontline KRAS Inhibition in NSCLC – Shirish Gadgeel, MBBS
10:50 AM - 11:00 AM
Beyond G12C: Emerging Therapeutic Strategies for Non-G12C KRAS Mutations
11:00 AM - 11:10 AM
Mechanisms of Resistance and Future Directions in KRAS-Driven NSCLC – Konstantin Dragnev, MD
11:10 AM - 11:30 AM
Case-Based Discussion
Session Chair: Nicholas Rohs, MD
11:30 AM - 11:40 AM
Managing Leptomeningeal Disease – Morana Vojnic, MD, MBA
11:40 AM - 11:50 AM
ctDNA and Minimal Residual Disease in NSCLC: Identifying Patients at Highest Risk of Recurrence
11:50 AM - 12:00 PM
Immunotherapy for Untreated Brain Metastases: What Have We Learned? – Sarah Goldberg, MD, MPH
12:00 PM - 12:10 PM
Gamma Knife Surgery in 2026: Pushing the Limits of Intracranial Disease Control – Douglas Kondziolka, MD
12:10 PM - 12:30 PM
Case-Based Discussion
Session Chair: Abraham Chachoua, MD
02:00 PM - 02:10 PM
Lung Cancer Screening in 2026: Who, When, and How? – Elaine Shum, MD
02:10 PM - 02:20 PM
Perioperative Immunotherapy in Resectable NSCLC: What Is Standard in 2026? – Jamie Chaft, MD
02:30 PM - 02:40 PM
Surgical vs Radiation Decision-Making in the Modern Era – Brendon Stiles, MD
02:40 PM - 03:00 PM
Case-Based Discussion
